SCHEMBL17666232

SCHEMBL17666232

N/C(=N\O)c1ccc2cc(O)ccc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F12 P00748 1/20 0.60
KDM1A O60341 6/20 0.52
RECQL P46063 1/20 0.47
KMT2A Q03164 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
CLK1 P49759 1/20 0.46
DYRK1A Q13627 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
LCK P06239 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
HIF1A Q16665 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19411892 1.00 F12 (0.60) F12KDM1ARECQLKMT2ARAB9A
SCHEMBL10802010 0.86 LCK (0.62) F12KDM1ARECQLKMT2ARAB9A
SCHEMBL103278 0.82 GRIN1 (0.59) RECQLKMT2ARAB9AMEN1NPC1
SCHEMBL7035626 0.82 GRIN1 (0.59) RECQLKMT2ARAB9AMEN1NPC1
SCHEMBL29786166 0.82 GRIN1 (0.59) RECQLKMT2ARAB9AMEN1NPC1
SCHEMBL2100967 0.78 LMNA (0.45) F12KDM1ARECQLKMT2ARAB9A
SCHEMBL2055355 0.78 LMNA (0.45) F12KDM1ARECQLKMT2ARAB9A
SCHEMBL771386 0.78 KDM1A (0.76) KDM1ARECQLKMT2ARAB9AMEN1
SCHEMBL1187298 0.78 KDM1A (0.76) KDM1ARECQLKMT2ARAB9AMEN1
SCHEMBL12873713 0.78 KDM1A (0.76) KDM1ARECQLKMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-11-23 US disclosed
US-20170298032-A1 SPHINGOSINE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-10-19 US disclosed
WO-2017172989-A1 SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS THORPE STEVEN BRANDON (US) 2017-10-05 WO disclosed
WO-2016054261-A1 SPHINGOSINE KINASE INHIBITORS LYNCH KEVIN (US) 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298032-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR2 F12 3265/4885KDM1A 1584/4885RECQL 4331/4885
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 F12 4488/4885KDM1A 4230/4885RECQL 2754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.